If you have been reading about WADA prohibited list and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide fragment | Not a full hormone |
| Molecular target | Proposed adipose tissue lipolysis | Receptor details uncertain |
| Typical research dose | Not established for clinical use | Doses vary across studies |
| Stability in solution | Limited; store cold | Avoid repeated freeze-thaw |
| Regulatory status | Not approved as a drug | Varies by country |
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
The Supreme Court consists of nine justices, including the chief justice of the United States, and decides cases before it by majority vote. When the Senate conducts an impeachment trial of a sitting president, the chief justice presides. Like other Article III judges, Supreme Court justices are nominated by the president and confirmed by the Senate and hold office during good behavior.
== Acquisitions == In February 2006, ASCP acquired the cytology product line of the Midwest Institute for Medical Education (MIME). At the time, it was the only national cytology proficiency testing provider. In 2009, ASCP acquired the medical technologist led National Credentialing Agency for Laboratory Personnel (NCA). The baccalaureate-level certification designations Medical Technologist (MT) and Clinical Laboratory Scientist (CLS) were replaced by Medical Laboratory Scientist, MLS(ASCP)CM. The BOC Board of Governors will be composed of five ASCP Fellows (pathologists), five ASCP laboratory professionals, four representatives of ASCLS, two representatives of the Association of Genetic Technologists, eight representatives from the eight participating societies respectively, and one public representative. The acquisition was criticized by AMT as doing little to further the standing of laboratory professionals. In 2021, ASCP acquired the Clinical Laboratory Management Association (CMLA). CMLA had advocated against laboratory personnel licensure as an unnecessary cost.
=== Depression === Some evidence supports the use of buprenorphine for depression. Buprenorphine/samidorphan, a combination product of buprenorphine and samidorphan (a preferential μ-opioid receptor antagonist), appears useful for treatment-resistant depression. A buprenorphine implant (developmental code name SK-2110) is under development by Shenzhen ScienCare Pharmaceutical in China for the treatment of refractory major depressive disorder.
Cyclophosphamide (Cytoxan, Procytox), Doxorubicin (Adriamycin) and Vincristine (Oncovin) Paclitaxel (Taxol) Irinotecan (Camptosar) Guidelines recommended as of 2018 that patients who relapse > 6 months from initial therapy should be retreated with the original chemotherapy regimen. For patients who relapse in < 6 months, single-agent chemotherapy either topotecan second-line therapy, or paclitaxel can be used.
In April 2025, Hegseth issued a directive to the secretary of the Army ordering on a sweeping overhaul, prioritizing defending the homeland and deterring China in the Indo-Pacific. Among others, the directive instructing a consolidated budget lines in unmanned systems, counter-drone systems and electronic warfare, force structure changes and expanded use of other transaction agreements. The directive also instructed to downsize or close redundant headquarters as well as merging Army Futures Command and Training and Doctrine Command, and merging four-star headquarters Army Forces Command with Army North and Army South into a single headquarters focused on homeland defense as well as the elimination of at least 20% of four-star general positions to enhance efficiency and operational effectiveness. Hegseth also signed a memorandum to reduce the Department of Defense's civilian workforce, aiming to eliminate duplicative efforts and excessive bureaucracy. The initiative includes offering voluntary early retirement and deferred resignation programs to incentivize top performers and enhance efficiency. That month, Hegseth received criticism from some Senate Democrats over alleged civilian deaths in the Yemen strikes.
Sources: en.wikipedia.org
== Habitat == Brown recluse spiders build asymmetrical (irregular) webs that frequently include a shelter consisting of disorderly threads. They frequently build their webs in woodpiles and sheds, closets, garages, plenum spaces, cellars, and other places that are dry and generally undisturbed. When dwelling in human residences they seem to favor cardboard, possibly because it mimics the rotting tree bark which they inhabit naturally. Human-recluse contact often occurs when such isolated spaces are disturbed and the spider feels threatened. Unlike most web weavers, they leave these lairs at night to hunt. Males move around more when hunting than the females, which tend to remain nearer to their webs.
== Poor usage of Iran's agricultural land == Approximately one-third of Iran's total surface area consists of arable farmland; however, less than one-fourth of this—equivalent to about one-tenth of the total land area—is actively cultivated. This limited cultivation is due to poor soil quality and inadequate water distribution across many regions. Of the cultivated land, less than one-third benefits from irrigation, while most rely on dry farming techniques. The most fertile soils are found in the western and northwestern regions of the country.
On October 21, 2025, partly as a consequence of the China–U.S. trade war that included China imposing restrictions on its sale of processed rare-earth elements, Trump signed a deal with Anthony Albanese, Prime Minister of Australia, over rare-earths and other critical minerals that are needed for commercial clean energy production and technologically advanced military hardware. They each committed to provide at least US$1bn (A$1.54bn) towards a number of projects worth $US8.5bn (A$13bn) in both countries over six months. The deal has been well received by the Australian rare-earths industry and the markets, and is important to the U.S. because rare earths are used in many technologies, including components of the Defense Force such as F-35 fighter jets and Tomahawk missiles. The deal is also seen as a major shift in economic alliances.
The first known archaeological evidence of usage was in Kariandusi (Kenya) and other sites of the Acheulian age (beginning 1.5 million years BP) dated 700,000 BC, although only very few objects have been found at these sites relative to the Neolithic. Manufacture of obsidian bladelets at Lipari had reached a high level of sophistication by the late Neolithic, and was traded as far as Sicily, the southern Po river valley, and Croatia. Obsidian bladelets were used in ritual circumcisions and cutting of umbilical cords of newborns. Anatolian sources of obsidian are known to have been the material used in the Levant and modern-day Iraqi Kurdistan from a time beginning sometime about 12,500 BC. Obsidian artifacts are common at Tell Brak, one of the earliest Mesopotamian urban centers, dating to the late fifth millennium BC. Obsidian was valued in Stone Age cultures because, like flint, it could be fractured to produce sharp blades or arrowheads in a process called knapping. Like all glass and some other naturally occurring rocks, obsidian breaks with a characteristic conchoidal fracture. It was also polished to create early mirrors. Modern archaeologists have developed a relative dating system, obsidian hydration dating, to calculate the age of obsidian artifacts.
Sources: en.wikipedia.org
==== Joint replacement ==== If the impact of symptoms of osteoarthritis on quality of life is significant and more conservative management is ineffective, joint replacement surgery may be used. Evidence supports joint replacement for both knees and hips as it is both clinically effective and cost-effective. People who underwent total knee replacement had improved quality of life, were feeling better compared to those who did not have surgery, and may have short- and long-term benefits for quality of life in terms of pain and function. The risk of death within the first 90 days after hip and knee replacements is less than 1%. The risk of serious complications (such as prosthetic joint infections which may require removal of the artificial joint, blood clots, joint dislocations) is less than 5% after hip or knee replacements. 90% of people with a hip replacement and 80% of those with a knee replacement reported little or no arthritis related pain after the procedure. Less than 10% of artificial knees and less than 20% of artificial hips required replacements over 20 years after the initial surgery. Arthroscopic debridement of the knee, also known as "joint resurfacing", is not recommended for the treatment of knee osteoarthritis and has a limited role in people who have osteoarthritis with a meniscal tear who have failed other treatments.
==== Eurasian plate ==== Eifel hotspot (8) 50°12′N 6°42′E, w= 1 az= 082° ±8° rate= 12 ±2 mm/yr Iceland hotspot (14) 64°24′N 17°18′W Eurasian Plate, w= 0.8 az= 075° ±10° rate= 5 ±3 mm/yr North American Plate, w= 0.8 az= 287° ±10° rate= 15 ±5 mm/yr Possibly related to the North Atlantic continental rifting (62 Ma), Greenland. Azores hotspot (1) 37°54′N 26°00′W Eurasian Plate, w= 0.5 az= 110° ±12° North American Plate, w= 0.3 az= 280° ±15° Jan Mayen hotspot (15) 71°00′N 9°00′W Hainan hotspot (46) 20°00′N 110°00′E, az= 000° ±15°
Atypical as Lederberg was at Asilomar, his optimistic vision of genetic engineering would soon lead to the development of the biotechnology industry. Over the next two years, as public concern over the dangers of recombinant DNA research grew, so too did interest in its technical and practical applications. Curing genetic diseases remained in the realms of science fiction, but it appeared that producing human simple proteins could be good business. Insulin, one of the smaller, best characterized and understood proteins, had been used in treating type 1 diabetes for a half century. It had been extracted from animals in a chemically slightly different form from the human product. Yet, if one could produce synthetic human insulin, one could meet an existing demand with a product whose approval would be relatively easy to obtain from regulators. In the period 1975 to 1977, synthetic "human" insulin represented the aspirations for new products that could be made with the new biotechnology. Microbial production of synthetic human insulin was finally announced in September 1978 and was produced by a startup company, Genentech. Although that company did not commercialize the product themselves, instead, it licensed the production method to Eli Lilly and Company. 1978 also saw the first application for a patent on a gene, the gene which produces human growth hormone, by the University of California, thus introducing the legal principle that genes could be patented. Since that filing, 20% of the more than 20,000 to 25,000 genes mapped in the human DNA have been patented.
Sources: en.wikipedia.org
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.
Because it is a fragment rather than full growth hormone, it is generally described as lacking growth-promoting effects. Some studies suggest it may influence fat metabolism without the same systemic growth effects, though evidence is limited.
Human trials have measured body weight, fat mass, lean mass, lipid levels, and adverse events. Most have been small or short-term, so conclusions about long-term outcomes are limited.
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.